Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?

Hämostaseologie
Minna Voigtlaender, Florian Langer

Abstract

Cancer patients with venous thromboembolism (VTE) are at increased risk for both bleeding and VTE recurrence. Anticoagulation with low-molecular-weight heparin (LMWH) is the standard of care during the initial and long-term treatment phase (i.e. during the first 3 - 6 months of therapy) based on its overall beneficial safety and efficacy profile compared to vitamin K antagonists (VKAs). The direct oral anticoagulants (DOACs) rivaroxaban, apixaban, edoxaban, and dabigatran are approved for the treatment of acute VTE, and the combined six phase-3 trials have included > 1500 patients with active cancer, as defined by variable selection criteria. Subgroup analyses of these patients, either pooled or separately reported, suggest that DOACs could be a safe and efficacious alternative to VKA therapy for the treatment of cancer-associated VTE. However, the populations of cancer patients included in the DOAC and LMWH trials are not comparable with regard to mortality and VTE risk, and no specific data from direct head-to-head comparisons of DOACs with LMWHs are currently available. The use of DOACs for the management of VTE in cancer is thus not recommended by clinical practice guidelines.

References

Jul 7, 1999·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·R WütschertH Bounameaux
Dec 16, 2000·The New England Journal of Medicine·H T SørensenJ A Baron
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz KabbinavarEmily Bergsland
Apr 8, 2003·Thrombosis Research·Meyer-Michel Samama, Grigoris T Gerotziafas
Jul 11, 2003·The New England Journal of Medicine·Agnes Y Y LeeUNKNOWN Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Veno
Dec 3, 2004·Journal of the American Society of Nephrology : JASN·Benjamin D HumphreysColm C Magee
Sep 27, 2006·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Steven R DeitcherUNKNOWN ONCENOX Investigators
Dec 6, 2006·The American Journal of Medicine·Russell D HullUNKNOWN LITE Trial Investigators
Feb 27, 2007·Journal of Thrombosis and Haemostasis : JTH·A A KhoranaG H Lyman
Dec 8, 2009·The New England Journal of Medicine·Sam SchulmanUNKNOWN RE-COVER Study Group
May 15, 2010·Thrombosis Research·Michael B Streiff, UNKNOWN National Comprehensive Cancer Center Network
Dec 7, 2010·The New England Journal of Medicine·Rupert BauersachsSebastian Schellong
Feb 12, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M S MarcolinoA L Ribeiro
Oct 20, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M MandalàUNKNOWN ESMO Guidelines Working Group
Mar 28, 2012·The New England Journal of Medicine·Harry R BüllerAnnelise Segers
Mar 6, 2013·International Journal of Clinical Pharmacology and Therapeutics·Jan StampfussWolfgang Mueck
May 15, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary H LymanUNKNOWN American Society of Clinical Oncology Clinical Practice
Jul 3, 2013·The New England Journal of Medicine·Giancarlo AgnelliUNKNOWN AMPLIFY Investigators
Jul 3, 2013·Journal of Thrombosis and Haemostasis : JTH·M CarrierUNKNOWN Subcommittee on Haemostasis and Malignancy for the SSC of the ISTH
Jul 12, 2013·Blood·Agnes Y Y Lee, Erica A Peterson
Jul 19, 2013·JAMA : the Journal of the American Medical Association·Francesco LapiSamy Suissa
Sep 3, 2013·The New England Journal of Medicine·Harry R BüllerPhil Wells
Dec 18, 2013·Circulation·Sam SchulmanUNKNOWN RE-COVER II Trial Investigators
Oct 3, 2014·BioMed Research International·Anne-Sophie DincqFrançois Mullier
Dec 30, 2014·Thrombosis Research·Raffaele PesaventoUNKNOWN RIETE Investigators
Jan 22, 2015·Electrolyte & Blood Pressure : E & BP·Gi-Su OhHong-Seob So
Feb 20, 2015·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Bernard Vrijens, Hein Heidbuchel
Mar 5, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V Launay-VacherB Sprangers
Mar 6, 2015·Thrombosis and Haemostasis·Sam SchulmanJörg Kreuzer
Apr 2, 2015·Journal of Thrombosis and Haemostasis : JTH·C W FrancisA K Kakkar
Feb 1, 2014·Clinical Kidney Journal·Norbert Lameire
Apr 17, 2015·Journal of Thrombosis and Haemostasis : JTH·J Beyer-Westendorf, G Siegert

❮ Previous
Next ❯

Citations

Jan 13, 2018·VASA. Zeitschrift für Gefässkrankheiten·Minna Voigtlaender, Florian Langer
May 24, 2019·Der Internist·J Renczes, E Lindhoff-Last

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.